


heterocycloalkyl group of the -C₁₋₆alkyl-heterocycloalkyl group of R^a, R^b, R^c, and R^d can be unsubstituted or substituted with 1, 2, 3, or 4 R¹⁴ substituents, wherein each R¹⁴ is independently selected from H, -OH, -N=N=N, halo, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -OC₁₋₆alkyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, phenyl, tolyl, -C(=O)C₁₋₆alkyl, -C(=O)O-C₁₋₆alkyl, N(CH₃)₂ or -SO₂-N(CH₃)₂; and

wherein n is independently in each instance an integer of 1, 2, 3 or 4.

In one example, the present disclosure comprises a compound of Formula I':



a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein:

Z is C or N;

Q is O or S;

W is CR^{WA}R^{WB} or C=O;

R^{WA} and R^{WB} are independently selected from H, C₁₋₃alkyl, halo, -OH, or -O-C₁₋₃alkyl;

b, represented by the symbol ----- is a single or double chemical bond which may be cis or trans;

R¹ is independently selected from H, halo, C₁₋₆alkylhalo, C₁₋₆alkyl, -(CH₂CH₂O)_nR^a, -SO₂R^a, -C(=O)R^a, -C(=O)OR^a, or -C(=O)NR^aR^b;

R² is selected from H, halo, -C₁₋₆haloalkyl, -C₁₋₆alkyl, -O-C₁₋₆alkyl, -C₂₋₆alkenyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -(CH₂CH₂O)_nR^a, -SO₂R^a, -C(=O)R^a, -C(=O)OR^a, -OC(=O)R^a, or -C(=O)NR^aR^b;

R³ is independently selected from H, -C₁₋₆alkylhalo, -C₁₋₆alkyl, -C₂₋₆alkenyl, -(CH₂CH₂O)_nR^a, -C(=O)R^a, -C(=O)OR^a, or -C(=O)NR^aR^b;

each of R⁴, R⁵, R⁶, R⁷, and R⁸ is independently selected from H, halo, -C₁₋₆haloalkyl, -C₁₋₆alkyl, -O-C₁₋₆alkyl, -C₂₋₆alkenyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -(CH₂CH₂O)_nR^a, -SO₂R^a, -C(=O)R^a, -C(=O)OR^a, -OC(=O)R^a, -C(=O)NR^aR^b, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

alternatively R³ and R⁴ together with the atoms to which they are bonded may form a 5- to 12-membered ring, optionally containing a heteroatom selected from a N, O or S atom, in addition to the S and N atoms present in the ring, wherein the ring may optionally contain at least one double bond; and the ring may be substituted with 0, 1, 2, or 3 R^{3A} substituents;

R^{3A} is independently selected from H, halo, -OH, C₁₋₆haloalkyl, C₁₋₆alkyl, O-C₁₋₆alkyl, C₂₋₆alkenyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -(CH₂CH₂O)_nR^a, -SO₂R^a, -C(=O)R^a, -C(=O)OR^a, -OC(=O)R^a, -C(=O)NR^aR^b;

each of R^{4A}, R^{5A}, R^{6A}, R^{7A}, and R^{8A} is independently selected from H, OH, halo, -C₁₋₆alkyl;

R^{7A} and R^{8A} are absent when b is a double chemical bond;

R⁹ is independently selected from H, -C₁₋₆haloalkyl, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -(CH₂CH₂O)_nR^a, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^b, -C₁₋₆alkyl-O-C₁₋₆alkyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

R^{9A} is independently selected from H, C₁₋₆haloalkyl, C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -(CH₂CH₂O)_nR^a, -SO₂R^a, -C(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^b, -NR^aR^b, -N=N=N, -C₁₋₆alkyl-O-C₁₋₆alkyl, a 6- to 12-membered aryl, a 6- to 12-membered heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycloalkyl and spiroheterocycloalkyl groups of the R^{9A} substituent can be unsubstituted or substituted with 1, 2, 3 or 4 R¹⁰ substituents independently selected from OH, halo, -NR^cR^d, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -OC₁₋₆alkyl, -C₁₋₆alkyl-OH, -C₁₋₆alkyl-O-C₁₋₆alkyl, C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, -SO₂R^c, -CN, -C(=O)NR^cR^d, -C(=O)R^c, -OC(=O)R^a, -C(=O)OR^c, a 6- to 12-membered aryl, a 6- to 12-membered heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups have 0, 1, 2, 3 or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

alternatively R⁹ and R^{9A} together with Q, W, and the C to which W and Q are bonded, may form a 3- to 12-membered monocyclic or bicyclic ring, optionally containing a heteroatom in addition to Q that is selected from N, O or S, wherein the ring

may contain a double bond, wherein the ring may optionally include a C=O group, and further wherein the ring optionally may be substituted by 1, 2, or 3 R¹¹ substituents;

R¹¹ is independently selected from OH, halo, -NR^cR^d, -C₁₋₆alkyl, -OC₁₋₆alkyl, -C₁₋₆alkyl-OH, -C₁₋₆alkyl-O-C₁₋₆alkyl, C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, -SO₂R^c, -CN, -C(=O)NR^cR^d, -C(=O)R^c, -OC(=O)R^a, -C(=O)OR^c, a 6- to 12-membered aryl or heteroaryl, a 6- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl group have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

wherein the -C₁₋₆alkyl of any of the R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R^{4A}, R^{5A}, R^{6A}, R^{7A}, R^{8A}, and R^{9A} substituents is unsubstituted or substituted by 1, 2 or 3 R¹² substituents independently selected from OH, -OC₁₋₆alkyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, halo, -O-haloC₁₋₆alkyl, -CN, -NR^aR^b, -(NR^aR^bR^c)_n, -SO₂R^a, -(CH₂CH₂O)_nCH₃, (=O), -C(=O), -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^a, -C(=O)NR^aR^b, -O-SiR^aR^bR^c, -O-(3- to 12-membered heterocycloalkyl), phenyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycloalkyl and spiroheterocycloalkyl groups of any of the R², R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² substituents can be unsubstituted or substituted with 1, 2, 3 or 4 R¹³ substituents independently selected from OH, halo, -C₁₋₆alkyl, -OC₁₋₆alkyl, -C₁₋₆alkyl-OH, -C₁₋₆alkyl-O-C₁₋₆alkyl, C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, -SO₂R^c, -NR^cR^d, -CN, -C(=O)NR^cR^d, -C(=O)R^c, -OC(=O)R^a, -C(=O)OR^c, -B(OH)₂, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

wherein each R^a, R^b, R^c, and R^d is independently H, OH, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₂₋₆alkynyl, -C₁₋₆alkyl-NR¹⁴R¹⁴, NR¹⁴R¹⁴, -SO₂R¹⁴, -(CH₂CH₂O)_nCH₃, (=O), -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹⁴, -C(=O)NR¹⁴R¹⁴, C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, -C₁₋₆alkyl-OH, benzyl, phenyl, a -C₁₋₆alkyl-3- to 12-membered heterocycloalkyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups and the heterocycloalkyl group of the -C₁₋₆alkyl-heterocycloalkyl


group have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, heterocycloalkyl, and the heterocycloalkyl groups of the -C₁₋₆alkyl-heterocycloalkyl group may include a C=O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S=O or SO₂;

the alkyl, aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, heterocycloalkyl and the heterocycloalkyl groups of the -C₁₋₆alkyl-heterocycloalkyl groups of R^a, R^b, R^c, and R^d can be unsubstituted or substituted with 1, 2, 3, or 4 R¹⁴ substituents independently selected from H, OH, -N=N=N, halo, -C₁₋₆alkyl, -OC₁₋₆alkyl,

C₁₋₆haloalkyl, -O-haloC₁₋₆alkyl, phenyl, tolyl, -C(O)C₁₋₆alkyl, -C(O)OCH₃, SO₂-phenyl, or -SO₂-N(CH₃)₂; and

n is independently, in each instance, an integer of 1, 2, 3 or 4.


In another example, the compound of Formula I' has Formula II'a:





(II'a)

or the stereoisomer thereof, the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable salt of the stereoisomer thereof.

In one aspect, the present disclosure provides a compound selected from:

















or the stereoisomer thereof, the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable salt of the stereoisomer thereof.

Claims

1. A compound, wherein the compound is selected from:









or the stereoisomer thereof, the pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable salt of the stereoisomer thereof.

2. The compound of Claim 1 or the pharmaceutically acceptable salt thereof.
3. The compound of Claim 1, wherein the compound is




, or is the pharmaceutically acceptable salt thereof.

4. The compound of Claim 1, wherein the compound is




, or is the pharmaceutically acceptable salt thereof.

5. The compound of Claim 1, wherein the compound is




, or is the pharmaceutically acceptable salt thereof.

6. The compound of Claim 1, wherein the compound is




, or is the pharmaceutically acceptable salt thereof.

7. A compound, wherein the compound is



, or is the pharmaceutically acceptable salt thereof.

8. A compound, wherein the compound is



9. A pharmaceutical composition comprising the compound of any one of Claims 1-7 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

10. A pharmaceutical composition comprising the compound of Claim 3 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition comprising the compound of Claim 4 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

12. A pharmaceutical composition comprising the compound of Claim 5 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

13. A pharmaceutical composition comprising the compound of Claim 6 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

14. Use of a compound according to any one of Claims 1-7 in the preparation of a medicament for treating cancer.

15. The use according to Claim 14, wherein the cancer is a hematologic malignancy.

16. The use according to Claim 14, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, non-small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acute myelogenous leukemia.

17. The use according to Claim 14, wherein the cancer is multiple myeloma, acute myelogenous leukemia, or non-Hodgkin's lymphoma.